Dr. Kane is committed to implementing new technologies that enhance access to care, quality of care, and outcomes while increasing the cost-effectiveness of schizophrenia treatment. He has been working on the development of new strategies for patient engagement, adherence monitoring, and clinical decision-making using advanced technologies such as live two-way video and similar telecommunications. He works closely with numerous academic, state, and federal agencies as well as advocacy groups to ensure the feasibility and sustainability of new models of technology-enhanced care.
Dr. Kane was a pioneer in the study of first-episode schizophrenia and conducted groundbreaking work with clozapine for treatment-resistant schizophrenia. He has continuously focused on both the therapeutic and adverse effects of psychotropic drugs, thereby informing benefit-to-risk considerations. Dr. Kane also devotes his efforts to standardizing the outcome measurements in psychiatric research and helping to ensure the translation of research into clinical practice. Since the beginning of his residency at Zucker Hillside Hospital in Glen Oaks in 1971, Dr. Kane has committed his career to unraveling the mysteries of this brain disorder